Shire PLC; market cap: $28.38bn (as of 06/11/2015) Dyax Corporation; market cap: $5.1bn (as of 06/11/2015) Introduction On November 2, Dublin-headquartered pharmaceutical company Shire Plc agreed to acquire the Massachusetts-based biopharma company Dyax Corporation for an upfront cash consideration of $5.9bn and an additional $646m payment contingent on the Read more…
Walgreens Boots Alliance; market cap (as of 30/10/2015) $91.3bn Rite Aid; market cap (as of 30/10/2015) $8.2bn Introduction Last week the pharma sector was shook up by a new deal: Walgreens Boots Alliance agreed to buy the smaller pharma rival Rite Aid in a transaction worth $17.2bn. The deal Read more…
Blackstone Group LP; market cap (as of 10/10/15): $39.6bn BioMed Realty Trust Inc; market cap (as of 10/10/15): $4.8bn The Deal in Brief On Thursday Blackstone Group LP agreed to buy landlord BioMed Realty Trust Inc, a supplier of office space to healthcare and biotech companies. This represents an Read more…
Teva Pharmaceuticals Industries Ltd. (TEVA); market cap (as of 02/10/2015): $51.05bn. Introduction Following a wave of consolidation in the healthcare industry, Teva Pharmaceuticals Industries Ltd. and Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa) announced on October 1 that they have entered into a definitive agreement under which Teva Read more…
Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…
AbbVie Inc.; market cap (as of 06/03/2015): $88.7bn Pharmacyclics Inc.; market cap (as of 06/03/2015): $19.3bn Introduction On March 4, the pharmaceutical company AbbVie, outbidding the competitor Johnson & Johnson, agreed to buy the cancer biotech company Pharmacyclics in a $21bn transaction. The Chicago based company will pay $261.25 per Read more…
Valeant Pharmaceuticals International, Inc.; market cap (as of 26/02/2015): US$76.68bn Salix Pharmaceuticals, Ltd.; market cap (as of 26/02/2015): US$10.07bn Introduction The pharmaceutical industry has undergone an intense period of consolidation in the past 18 months which is far from over as the big players take advantage of the Read more…
Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…
Bayer AG Market Cap (09/05/2014): $115.17bn Merck & Co., Inc. Market Cap (09/05/2014): $161.23bn On May 6th, Bayer announced the acquisition of Merck’s consumer care business for a hefty $14.2bn, surpassing competing offers from Boehringer-Ingelheim and Reckitt Benckiser and, thus becoming the second largest company in over-the-counter (OTC) products worldwide. Read more…
Actavis Plc, Market Cap (as of 21/02/14): $38.35bn Forest Laboratories Inc, Market Cap (as of 21/02/14): $26.36bn On February 18th, 2014 the Dublin-based generic drug maker, Actavis PLC, announced an acquisition of the New York-based specialty drug maker, Forest Laboratories Inc, in a $25bn cash-and-equity deal. If successfully completed, the Read more…
Merck KGaA Market Cap (as of 06/12/13): €27.84bn AZ Electronic Materials SA Market Cap (as of 06/12/13): €1.79bn On December 5, 2013 the Darmstadt-based German drug and chemicals company, Merck KGaA, announced an agreement with the Board of Directors of AZ Electronic Materials SA (AZ) regarding a recommended $2.57bn all-cash Read more…
Shire PLC Market Cap (as of 15/11/13): £15.7bn ViroPharma Inc. Market Cap (as of 15/11/13): $3.3bn Monday, November 11th brought about the much rumored king-size deal of the year in the pharmaceutical sector: Shire PLC of Ireland acquired ViroPharma Inc., a US-based niche company focused on rare diseases, for a Read more…
Abbott has endured a strong rally that took out $35 level, leaving the stock set to benefit from the momentum that is being built up following the positive Q1 results. The overall sector is becoming more popular in the screens of traders as Life Technologies Corp. it is set to Read more…
Elan Corporation PLC – Market Cap (as of 01/03/13) : $6.7bn Royalty Management, LLC On Monday, 25 February 2013, Royalty Pharma, the American private equity firm investing in acquiring drug royalties, made an indicative offer to acquire all the outstanding shares of Elan Corporation, the Irish biotech company listed in Read more…